If you are interested in gaining access to our investigational medicines, we encourage you to speak with your physician about the possibility of enrolling in a clinical trial. Learn more Learn more If you would like access to our investigational medicines, speak with your physician about enrolling in a clinical trial.

Despite many recent advances in cancer treatments with breakthrough therapies, a large proportion of patients unfortunately develop resistance to their current treatment and are in need of new and better treatment options. Bolt is committed to addressing this unmet medical need.

What is Immuno-oncology?

Cancer can upregulate the expression of various immunosuppressive factors in the tumor microenvironment that inhibit the normal function of immune cells and limited in their ability to create a productive anti-tumor immune response. Immuno-oncology approaches seek to harness the body’s own immune system to fight cancer. Our Boltbody ISACs act by seeking to reengage the immune system to generate an new anti-tumor immune response by activating the innate immune system which also leads to an adaptive immune response.

What is HER2?

Human epidermal growth factor receptor 2, or HER2, is a gene that encodes a protein that promotes cell growth and differentiation. HER2 protein overexpression and gene amplification have been documented across multiple cancers.  Therapeutics targeting of HER2 have had a major impact on patients with HER2-positive breast and gastric cancer, but there remains a huge amount of work to be done highlighted by a significant individual and global patient need.

What is BDC-1001?

Our lead product candidate, BDC-1001, is our HER2 Boltbody ISAC that seeks to improve therapeutic outcomes for patients with HER2-expressing tumors:

  1. HER2-positive breast and gastric cancer refractory to existing anti-HER2 therapies,
  2. Tumors with lower expression of HER2 that are not eligible for approved therapies, and
  3. Other HER2-positive tumors not eligible for approved therapies.

In addition, our innovative BDC-1001 approach seeks to address this critically important unmet medical need not only in patients with advanced tumors, but also in adjuvant settings.

BDC-1001, is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including subsets with HER2-low tumors. BDC-1001 is an ISAC comprised of a HER2-targeting biosimilar trastuzumab conjugated to one of our proprietary TLR7/8 agonists to maximize the potential anti-tumor response.

How can I participate?

If you are interested in gaining access to our investigational medicines, we encourage you to speak with your physician about the possibility of enrolling in a clinical trial.